FDA approves Sanofi's diabetes drug for children amid regulatory tensions and systemic healthcare pressures
Original framing: “STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes” — STAT News
The scientific evidence supporting Teplizumab for pediatric use is robust, but the approval process raises questions about the independence of regulatory bodies. The drug's efficacy in clinical trials is well-documented, yet the political nature of the approval highlights a gap between science and governance.
The approval of Sanofi's diabetes drug for children is not just a regulatory event but a systemic reflection of power dynamics between science, politics, and corporate interests.
Indigenous and traditional knowledge systems offer alternative models of care that are often excluded from clinical and regulatory processes. A cross-cultural perspective reveals the limitations of a purely Western biomedical approach, while historical analysis shows how political and corporate forces have shaped health outcomes for marginalized communities. To move forward, we must reform regulatory structures to ensure transparency and independence, expand clinical inclusivity, and integrate diverse healing practices into public health frameworks. Only through such systemic change can we achieve equitable and sustainable healthcare solutions.